Key result
Cardiometabolic comorbidities drive atrial cardiomyopathy and AF, increasing dementia risk via stroke and non-stroke pathways.
Why the study?
The mechanisms linking cardiovascular and metabolic comorbidities to cognitive impairment in patients with atrial fibrillation are not fully elucidated.
This narrative review synthesizes evidence that metabolic comorbidities promote atrial cardiomyopathy, which may underlie both atrial fibrillation and stroke-independent cognitive decline, highlighting weight management and comorbidity control as potential targets to preserve cognition.
Answers are grounded in this paper and cite their sources.
May support comorbidity control to mitigate AF-related cognitive decline; hypothesis-generating, requiring prospective trials before practice change.
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice with implications on long-term outcomes. Metabolic disorders including diabetes mellitus and obesity are independent predictors of atrial fibrillation and present therapeutic targets to reduce both the incidence and duration burden of atrial fibrillation. The presence of pericardial fat in direct contact with cardiac structures, as well the subsequent release of proinflammatory cytokines, may play an important role in this connection. Atrial fibrillation is an independent predictor of cognitive impairment and dementia. While clinical stroke is a major contributor, other factors such as cerebral hypoperfusion and microbleeds play important roles. New evidence suggests that atrial fibrillation and cognitive impairment may be downstream events of atrial cardiomyopathy, which may be caused by several factors including metabolic syndrome, obesity, and obstructive sleep apnea. The mechanisms linking these comorbidities to cognitive impairment are not yet fully elucidated. A clearer understanding of the association of AF with dementia and cognitive impairment is imperative. Future studies should focus on the predictors of cognitive impairment among those with AF and aim to understand the potential mechanisms underlying these associations. This would inform strategies for the management of AF aiming to prevent continued cognitive impairment.
No takes yet. Share an insight, caveat, or question.
AlTurki et al. (2019) conducted a review in Atrial fibrillation, metabolic comorbidities, and cognitive impairment/dementia. Cardiovascular and metabolic comorbidities (e.g., obesity, diabetes mellitus, metabolic syndrome, hypertension) was evaluated on Cognitive impairment and dementia in patients with atrial fibrillation. Cardiovascular and metabolic comorbidities independently predict atrial fibrillation and may drive atrial cardiomyopathy, contributing to cognitive impairment and dementia via stroke and non-stroke mechanisms.
Synapse has enriched 10 related papers. Consider them for comparative context: